A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects

被引：0
作者：
Ya-nan Liu
Jie Huang
Can Guo
Shuang Yang
Ling Ye
Shu-ting Wu
Xing-fei Zhang
Xiao-yan Yang
Cui-cui Han
Qi Pei
Lu Huang
Qing-nan He
Guo-ping Yang
机构：
[1] Central South University,Clinical Trails Center of the Third Xiangya Hospital
[2] Central South University,XiangYa School of Pharmaceutical Sciences
[3] Qilu Pharmaceutical Co. Ltd,Department of Pharmacy of the Third Xiangya Hospital
[4] Central South University,Research Center for Drug Clinical Evaluation
[5] Central South University,Department of Pediatrics of the Third Xiangya Hospital
[6] Central South University,Center for Clinical Pharmacology of the Third Xiangya Hospital
[7] Central South University,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 85卷
关键词：
QL1101; Bevacizumab; Biosimilar; Pharmacokinetics; Safety; Immunogenicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：555 / 562
页数：7
相关论文
共 105 条
[1]  
Rugo HS(2016)A clinician's guide to biosimilars in oncology Cancer Treat Rev 46 73-79
[2]  
Linton KM(2016)Therapeutic monoclonal antibodies and derivatives: historical perspectives and future directions Biotechnol Adv 34 1149-1158
[3]  
Cervi P(2019)Biosimilar medicines used for cancer therapy in Europe: a review Drug Discov Today 24 293-299
[4]  
Rosenberg JA(2004)Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 581-611
[5]  
Jacobs I(2005)Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 1011-1027
[6]  
Rodgers KR(2004)Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 391-400
[7]  
Chou RC(2017)Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial JAMA 317 2392-2401
[8]  
Santos SB(2016)Is there room for bevacizumab in metastatic breast cancer? Lancet Oncol 17 1175-1176
[9]  
Sousa LJ(2017)Bevacizumab in adjuvant treatment of non-small-cell lung cancer Lancet Oncol 18 1558-1560
[10]  
Silva AC(2017)Renal cell carcinoma Nat Rev Dis Primers 3 17009-4370
12345678910